<DOC>
	<DOCNO>NCT00421525</DOCNO>
	<brief_summary>This Phase I/II , open-label , multi-center study conduct patient recurrent refractory multiple myeloma fail least two prior standard systemic treatment .</brief_summary>
	<brief_title>Phase I/II Study hLL1 Multiple Myeloma</brief_title>
	<detailed_description>All patient receive hLL1 administer intravenously twice weekly 4 consecutive week . Cohorts 3-6 patient receive escalate dos hLL1 order determine maximum tolerate dose ( MTD ) administration schedule . Up approximately 30 additional patient enter one dose level MTD order determine optimal dose subsequent study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<criteria>Able provide sign , informed consent ; Male female , &gt; /=18 year old ; Meets clinical trial criterion diagnosis multiple myeloma ( Appendix 1 ) Stage II III study entry DurieSalmon staging , either renal function subclassification ( A B ) allow ( Appendix 2 ) . Secretory multiple myeloma one criterion measurable disease ( serum M protein &gt; 1.0 gm/dl measure serum protein electrophoresis , serum free light chain measurement &gt; 200 mg/dl , urinary M protein excretion &gt; 200 mg/24 hour ) ; Refractory relapse least two prior standard systemic antimyeloma treatment regimens ; Adequate performance status ( Karnofsky Scale &gt; /= 60 % ) ; Life expectancy least 6 month ; Adequate hematologic status within 2 week study drug administration : Hemoglobin &gt; 8.0 g/dL platelet &gt; 50,000/mm3 ( without transfusion hematologic support within 7 day laboratory test ) White blood count ( WBC ) &gt; 2,000/mm3and absolute neutrophil count ( ANC ) &gt; 1,000/mm3 ( without use colony stimulate factor within 7 day laboratory test ) Adequate renal function : serum creatinine &lt; 1.5 x upper limit normal ( ULN ) ; Adequate hepatic function AST ALT &lt; 2.5 x ULN ; Total bilirubin &lt; 1.5 x ULN Pregnant lactate woman . Women childbearing potential fertile men practice unwilling practice birth control enrol study least 12 week last hLL1 infusion ; Prior chemotherapy , immunotherapy , radiotherapy , plasmapheresis , kyphoplasty , major surgery within 4 week ; prior stem cell transplant within 12 week ; prior treatment rituximab within 6 month . Must recover toxicity prior treatment ; Prior therapy murine , chimeric , human humanize monoclonal antibody , unless HAHA test negative ; Prior treatment investigational agent within 3 month , unless complete followup , study , agree Sponsor ; Prior malignancy within 5 year , exclude multiple myeloma , nonmelanoma skin cancer cervical carcinoma situ ; Known HIV positive , hepatitis B C positive ; Known autoimmune disease presence autoimmune phenomenon ; Systemic infection require antiinfectives within 7 day first dose study drug ; Substance abuse concurrent medical condition , investigator 's opinion , could confound study interpretation affect patient 's ability tolerate complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>Myeloma , Plasma-Cell</keyword>
	<keyword>PLASMACYTOMA</keyword>
</DOC>